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ABSTRACT 25 
A particle engineering method that adsorbs a microfine vinyl polymer coat to crystalline drug 26 
microparticles has been shown to be an effective way to control delivery. However, the means by 27 
which the functional performance of such microparticles is altered by the behaviour of the 28 
polymers in the microparticle coat remains unclear. The aim of this study was to determine the 29 
influence of vinyl polymer coating on the in vitro delivery characteristics of intranasal lorazepam 30 
microparticles. A series of four, similarly sized (ca. 10 µm), lorazepam-rich microparticles with 31 
different polymer coats were generated. The absorption of the polymer coats appeared to disrupt 32 
lorazepam solid state dimer formation in the microparticles, which manifested in a reduction in 33 
drug melting point. Mildly cohesive particles (aerodynamic diameter of 32 µm) that allowed rapid 34 
drug release (ca. 80% in 5 min) were generated when partially hydrolysed PVA dominated the 35 
microparticle coat, whilst fully hydrolysed PVA reduced particle cohesion and retarded drug 36 
release (ca. 15% release in 5 min). Infrared analysis showed that the properties of the 37 
microparticles were dictated by the strength of the hydrogen bonding in the polymer coat and not 38 
the strength of coat adsorption that was facilitated by hydrogen bond formation between the 39 
hydroxyl groups of the PVA and the hydroxyl group at position C3 of the lorazepam diazepine 40 
ring.  41 
 42 
 43 
 44 
 45 
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INTRODUCTION 47 
 48 
Insomnia is commonly treated by oral administration of lorazepam, but the 1-2 hour delay to 49 
induce significant sedation is a major barrier to effective therapy. This delayed onset can often 50 
result in over dosing due to the patient taking another dose in an attempt to initiate the clinical 51 
effects. Intranasal administration of lorazepam could dramatically improve the immediacy of 52 
sedation. The large surface area of the nasal mucosa provides rapid absorption into the systemic 53 
circulation and the possibility of direct access to the central nervous system (Costantino et al., 54 
2007). Nasal delivery also has the benefits of being non-invasive and avoiding ‘first-pass’ 55 
metabolism.  56 
 57 
Attempts to reformulate lorazepam have been hindered by its lack of aqueous solubility (ca. 0.08 58 
mg/ml) (Moffat et al., 2004) and poor chemical stability (Archontaki et al., 1999). Although 59 
dissolving this active agent in propylene and polyethylene glycol solutions appears to resolve the 60 
chemical stability issues, there have been reports of possible toxicity associated with these 61 
solubilisers (Laine et al., 1995; Cawley, 2001). Considering the physicochemical properties of 62 
lorazepam, formulating this drug in the form of a dry powder would appear to be a sensible 63 
approach, but a particulate based system would require efficient aerosolisation and rapid 64 
dissolution to ensure a superior clinical outcome to the oral dosage form. Applying an 65 
appropriate particle engineering method to generate a lorazapam rich microparticle is one 66 
potential means to achieve this.   67 
 68 
It has been demonstrated that efficient particle engineering facilitates fine control over the size, 69 
density and morphology of a material which can be used to influence the behavior of a delivery 70 
system. For example, Bao and Zhao (2010) reported a membrane emulsification approach that 71 
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could produce uniform microparticles with controllable size. Edwards et al. (1997) utilized a 72 
spray drying method for the formation of low density porous poly (lactic acid-co-glycolic acid) 73 
particles containing insulin and testosterone. Chew and Chan (2001) modified the surface 74 
morphology of bovine serum albumin microparticles to generate ‘corrugated particles’. Rehman 75 
et al. (2004) employed supercritical fluids to modify the crystallinity of terbutaline sulphate 76 
microparticles. Rogers et al. (2003) attempted to use a method of spray-freezing into liquid to 77 
manufacture novel amorphous danazol microparticles with improved dissolution characteristics. 78 
However, many of these methods show limited control over drug crystallinity and the generated 79 
particles often exhibit an extremely diverse morphology.  80 
 81 
One approach that has the potential to overcome the aforementioned issues is the generation of 82 
microparticulate carriers using an engineering technique that facilitates biocompatible 83 
macromolecule adsorption. Vinyl polymers such as poly(vinyl alcohol) (PVA) and poly(vinyl 84 
pyrrolidone) (PVP) have previously been shown to modify microparticle behavior in inhaled 85 
formulations (Buttini et al., 2008a,b), whilst maintaining excellent control of physical stability in 86 
both the dry state and in suspension (Jones et al., 2006a,b). The biocompatible macromolecule 87 
coating process is facilitated when vinyl polymers are employed as the coating agents by their 88 
ability to spontaneously adsorb onto the surface of hydrophobic drugs in aqueous solutions 89 
(Buttini et al., 2008b). Coating using vinyl polymers is known to proceed in a multilayered 90 
manner as a result of the intra and intermolecular hydrogen bonding that occurs between the 91 
vinyl polymer chains (Buttini et al., 2008a,b).   92 
 93 
The aim of this study was to investigate how an adsorbed vinyl polymer coat influenced the key 94 
delivery characteristics of intranasal lorazepam microparticles. In order to achieve this, a specific 95 
series of vinyl polymer-coated microparticles were generated. The method of Buttini et al. 96 
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(2008a,b) was manipulated in order to modify the nature of polymer adsorption whilst 97 
maintaining a constant final particle diameter. In total, a series of four test microparticles were 98 
generated using a mixture of PVA and PVP which was varied to generate a ‘standard’ particle, 99 
similar to that produced previously (Lorzpva) (Buttini et al., 2008a); a particle that had a coat 100 
dominated by fully hydrolysed PVA, i.e. a coat with extensive intra-molecular hydrogen bonding 101 
(HyLorzpva); a particle with a high viscosity coat (HwLorzpvp) and a particle where a high 102 
proportion of PVP was employed (HpLorzpvp) (Table 1). The interaction of the two polymers with 103 
each other (Fourier Transform Infrared (FT-IR) spectrometry analysis) and with the drug 104 
(differential scanning calorimetry), an assessment of particle cohesiveness (impaction assessment) 105 
and drug release (modified United States Pharmacopeia (USP) dissolution) was compared in an 106 
attempt to elucidate the influence of the polymer employed in the adsorption process upon the 107 
particle behavior. 108 
 109 
MATERIALS AND METHODS 110 
 111 
Materials 112 
 113 
Lorazepam (Ph Eur) was supplied by Cambrex Profarmaco (Milano, Italy). Potassium dihydrogen 114 
orthophosphate and high performance liquid chromatography (HPLC) grade orthophosphoric 115 
acid, cylcohexane, water, methanol, ethanol and acetonitrile were all purchased from Fisher 116 
Scientific (Loughborough, UK). Formic acid, 1-chlorobutane, sodium chloride and sodium 117 
dodecyl sulfate (SDS) were supplied by Sigma-Aldrich Ltd. (Poole, UK). PVA 28-99 and PVA 118 
23-88 were supplied by KSE (Troisdorf, Germany). PVP (Kollidon 17) and Solutol HS 15 were 119 
supplied by BASF (Wantage, UK). PVP (Kollidon 90) was supplied by ISP (Calvert City, USA) 120 
and ammonium solution 25% by BDH (Poole, UK).  121 
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 122 
Microparticle Production 123 
 124 
Approximately 1.0 g of lorazepam (6.73 µm) was weighed in to an amber flask (100 ml) which 125 
was then filled with an aqueous solution containing mixtures of PVA and PVP of various grades 126 
and concentrations to produce the four suspensions (Table 1). These suspensions were 127 
spray-dried using a Buchi 191 bench top spray drier (Buchi, Switzerland). During spray-drying 128 
the suspensions were held at ambient temperature (20 ± 2
o
C) with the exception of HpLorzpvp 129 
which was heated to 80°C and agitated by constant magnetic stirring to ensure adequate 130 
suspension stability during manufacture (Stuart Scientific, Stone, UK). The inlet temperature of 131 
the spray-drier apparatus was maintained at 180ºC, the nozzle air flow at 650 ml.min
-1
, the 132 
atomisation flow at 70% and a feed rate at 3 ml.min
-1
. The spray-dried particles were collected 133 
on wax paper and stored under desiccation until required for further analysis. The yield of the 134 
process was calculated (Eq. 1). 135 
 136 
100
suspension the in  masssolid Initial
drying spray post particles of Mass
%)( yield       (Eq. 1) 137 
 138 
The lorazepam content uniformity of the spray-dried microparticles was tested by HPLC. A 10 139 
mg aliquot of each microparticle batch was added to 100 ml of an ethanol/water co-solvent 140 
mixture (1:1, v/v), the solution was diluted 1:10 (v/v) using the same solvent and the lorazepam 141 
content assayed by HPLC. Lorazepam content in each formulation was calculated by dividing 142 
the drug mass by the mass of the particles post spray-drying and the relative standard deviation 143 
was used as the indication of drug content uniformity (n = 6). 144 
 145 
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Laser Diffraction Particle Size Analysis 146 
 147 
The size (volume mean diameter, (VMD)) of the spray-dried lorazepam microparticles was 148 
determined using laser diffraction (Mastersizer X, Malvern, UK). The lens used was 100 µm, 149 
active beam length 14.3 mm and the sample unit was a MS-7 (magnetically stirred cell). A 150 
concentrated sample of each formulation was suspended in lorazepam-saturated cyclohexane 151 
before being sonicated in a water bath (Model F5100b; Decon Laboratories, UK) for 10 s to 152 
ensure dispersion of any aggregates. The samples were added drop-wise into the MS-7 cell 153 
containing drug-saturated cyclohexane with continuous magnetic stirring until an ideal 154 
obscuration (10-30%). Measurement was repeated eight times for each sample and three samples 155 
measured per batch using a randomised sampling procedure. 156 
 157 
Thermogravimetric Analysis 158 
 159 
The volatile content of the spray-dried microparticles was determined using a 2050 160 
thermogravimetric analyser (TGA) (TA instruments, Crawley, UK). Samples of each 161 
microparticle batch (approximately 10 mg) were assessed in individual open aluminium pans and 162 
placed into the sampler of the TGA instrument. A heating rate of 10
o
C.min
-1
 from 25
o
C to 300
o
C 163 
was used to determine the percentage of volatiles present in the spray-dried samples.  164 
 165 
Differential Scanning Calorimetry 166 
 167 
Thermal measurements were carried out using a 2920 modulated differential scanning 168 
calorimetry (DSC) equipped with thermal solutions universal analysis software® (TA 169 
Instruments, Crawley, UK). Prior to analysis the DSC was calibrated using an indium standard. 170 
Intranasal lorazepam delivery 
 8 
Approximately 2 mg of each sample was analysed by placing it into hermetically sealed pans 171 
(TA instruments, Crawley, UK) with a pinhole in the roof. Samples were heated with a 172 
modulated heating method (+/- 1
o
C.min
-1
) using a heating rate of 10
o
C.min
-1
 from 25
o
C to 173 
300
o
C. Oxygen free nitrogen was used as the cell purge gas with a flow rate of 100 ml.min
-1
. 174 
The melting temperature of the sample was taken as the onset of the endothermic peak of the 175 
resultant thermograms.  176 
 177 
Fourier Transform Infrared Spectroscopy 178 
 179 
Absorption infrared spectra of the polymers, lorazepam and coated microparticles were recorded 180 
at room temperature using a Perkin-Elmer FTIR 1720X spectrometer (Perkin-Elmer, UK) fitted 181 
with a DurasamplIR attenuated reflectance (ATR) unit (SensIR Technologies, UK). The 182 
machine was calibrated with a polystyrene standard as per the manufacturer’s instructions. The 183 
powders were pressed directly onto the ATR crystal using the sampling unit. Each sample was 184 
run at a 4 cm
–1
 resolution over the 400-4000 cm
-1
 range.  185 
 186 
Particle Aerosolisation Assessment 187 
 188 
The assessment of particle aerosolisation behaviour was performed using a Multi- Stage Liquid 189 
Impinger (MSLI) (Astra Draco, Lund, Sweden) and its design and working mechanism are 190 
detailed in Pharmacopeia (US Pharmacopeia XXXIII, 2010). A simple glass delivery device 191 
(made in house) was attached to the upper end of a stainless steel 90° induction port on top of the 192 
impinger. Ethanol (20 ml) was added to each stage of the MSLI and the rubber stoppers were 193 
inserted before the impinger was tilted to wet the stoppers and reduce electrostatic charge. A 2 mg 194 
sample was weighed directly into the delivery device. The vacuum pump was turned on (30 195 
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L.min
-1
) while covering the end of the delivery device containing the powder to prevent ejection. 196 
Uncovering the end of the device exposed the powder bed to the airflow which released the 197 
material into the MSLI. The pump continued to draw air through the MSLI 10 s post dose release. 198 
The particle size cut off points for each stage of the impinger were calculated as 18.39 µm at stage 199 
1, 9.62 µm at stage 2, 4.38 µm at stage 3 and 2.40 µm at stage 4, any smaller material was collected 200 
on a filter at the base of the impinger. The MSLI was carefully rotated and inverted, avoiding 201 
transfer of solution between stages, in order to wash all internal surfaces of each stage of the 202 
impinger. The metal throat was rinsed into Stage 1 and the connecting tube between each stage 203 
was washed into each subsequent stage using ethanol. Each stage in turn was then emptied into a 204 
50 ml volumetric flask and washed with approximately 20 ml of an ethanol/water co-solvent (1:1, 205 
v/v). The rubber stoppers were also rinsed into the corresponding volumetric flask (50 ml) for each 206 
stage. All samples were analysed by HPLC. Mass median aerodynamic diameters were calculated 207 
by interpolation as per the European Pharmacopeia method (Anon, 2002). 208 
 209 
Dissolution Testing 210 
 211 
To determine the release rate of lorazepam, a modified USP dissolution method was developed 212 
since it is practically difficult to keep the particles in the dissolution media when employing 213 
traditional USP methods. The dissolution apparatus was performed in a water bath at 37ºC 214 
(continually monitored using a temperature probe). The rotation speed of the apparatus was 215 
calibrated and set at 100 rpm. The dissolution vessels were filled with 500 ml of water 216 
containing SDS at either 0.2 or 0.5%, w/v (lorazepam solubility: 416.5 µg/ml at 0.2% and 217 
1413.95 µg/ml at 0.5%). A known weight of lorazepam alone or in the form of the spray-dried 218 
microparticles (ca. 2-5 mg of drug; sink conditions maintained in all experiments) was applied as 219 
a thin layer to a piece of double sided PVA sellotape which was attached to a small metal disc. 220 
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The metal disc was screwed directly on to the end of the stirring rods and inserted into the 221 
dissolution vessel. Samples (1 ml) were taken at a range of time points up to 60 min for HPLC 222 
assay and immediately replaced with the same volume of fresh, pre-warmed dissolution media.  223 
 224 
Lorazepam Assay 225 
 226 
A reverse-phase (RP) HPLC method was used to quantify lorazepam. The analysis was 227 
performed using a Waters HPLC system which consists of an autosampler (Waters 717 plus), a 228 
pump controller (Waters 600E), a dual lambda absorbance detector (Waters 2487) and 229 
Millennium software (Version 4.0). A Chromolith
®
 performance RP-18e (100 x 4.6 mm) column 230 
with a Chromolith
®
 RP-18e guard cartridge (5 x 4.6 mm) was used for the separation. The 231 
mobile phase consisted of 75% (v/v) water (pH 2.1, adjusted with orthophosphoric acid) and 232 
25% (v/v) acetonitrile containing 35 mM potassium dihydrogen orthophosphate with a flow rate 233 
of 2 ml.min
-1
. The sample injection volume was 10 µl and UV detection was at 220 nm. The 234 
resulting lorazepam retention time was 12 min. The needle wash was performed using a mixture 235 
of methanol and water (90:10, v/v). The method was validated in terms of system suitability, 236 
sensitivity (LOD = 0.157 µg/ml ± 0.094, LOQ = 0.477 µg/ml ± 0.285), linearity (> 0.999), 237 
accuracy (between 95-105%) and precision (intermediate precision between 0.95 and 1.05) and 238 
shown to be ‘fit for purpose’ for the analysis of lorazepam. 239 
 240 
Statistical Analysis 241 
 242 
All data were presented as mean ± standard deviation and statistical analysis was performed 243 
using SPSS version 16.0. A statistically significant difference was determined at a minimal level 244 
Intranasal lorazepam delivery 
 11 
of significance of 0.05. All data were checked in terms of normality (Kolmogorov-Smirnov test) 245 
and analysed using one-way analysis of variance (ANOVA) with a Tukey HSD post hoc test. 246 
 247 
RESULTS 248 
  249 
Particle Production and Characterisation 250 
 251 
The spray-drying process successfully generated a series of flowable powders. The production 252 
yields ranged from 17-40%, which was considered typical of such a manufacture process 253 
(Buttini et al., 2008a; Sollohub and Cal, 2010). The median particle diameter of the unprocessed 254 
lorazepam was 6.73 ± 0.08 µm (Table 2). Adsorbing the polymer coats to the drug, independent 255 
of polymer type and content, significantly increased the particle size (p < 0.05). The 256 
microparticle coats in which PVP controlled the coat properties generated the largest particles 257 
(HpLorzpvp –10.74 ± 0.06; HwLorzpvp –11.96 ± 0.16 µm) (Table 2). Altering the PVA grade had 258 
no discernable effect on particle size (HyLorzpva – 9.45 ± 0.05; Lorzpva – 9.85 ± 0.42 µm, no 259 
significant difference, p > 0.05). Despite the relatively high variability (10-15%), the final 260 
lorazepam content of the polymer-coated microparticles appeared to be greatest when there was 261 
a high initial drug loads added to the feed stock prior to spray-drying. For example, when 59% 262 
w/w lorazepam was loaded onto the Lorzpva microparticle batch, 39 ± 14% lorazepam was 263 
retained after processing. In a similar manner the 93% w/w lorazepam that was present initially 264 
in the HyLorzpva batch generated microparticles containing 89 ±15% w/w lorazepam.  265 
 266 
The absence of any weight loss in the TGA profiles of the microparticle samples (up to a 267 
temperature of 120ºC) indicated a lack of significant bound water (< 0.1 %). The absence of 268 
water uptake by that material was not unexpected as the crystalline drug was suspended in the 269 
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water and the drying conditions of the processing method were optimised previously (Buttini et 270 
al., 2008b). The DSC thermograms of the microparticle samples displayed two thermal events , 271 
(data not shown), one which was identified as the lorazepam melting peak at 159-170°C and a 272 
second which was identified as lorazepam/polymer degradation at >310°C (degradation 273 
confirmed by weight loss). The lorazepam alone had a melting onset temperature of ca. 190°C 274 
(82°C in Jug and Becirevic-Lacan, 2008) and this decreased as the polymer content of the 275 
microparticles increased.  For example, HyLorzpva, which had a lorazepam content of ca. 90%, 276 
displayed a melt at 170°C, whereas Lorzpva which had a lorazepam content of ca. 40% displayed 277 
at melt at 159°C. The reduction in melting point was mirrored by a corresponding reduction in 278 
melting enthalpy, for example lorazepam particles displayed a melt enthalpy of 245.7 J/g/ºC 279 
compared to the enthalpy of HyLorzpva and Lorzpva which had a melt enthalpy of 13 and 6 J/g/ºC, 280 
respectively.  281 
  282 
The two grades of PVA displayed typical FTIR traces prior to adsorption onto the lorazepam. 283 
The OH peak for the partially hydrolysed material was recorded at 3301 cm
-1
 and the hydrogen 284 
bonded and non-hydrogen bonded C=O peaks were present at 1715 and 1735 cm
-1
, respectively 285 
(Figure 1). The lack of significant acetate groups in the fully hydrolysed PVA was demonstrated 286 
by the absence of the C=O peaks. In addition, the fully hydrolysed PVA showed a more 287 
restricted OH environment, probably due to more extensive intermolecular hydrogen bonding, 288 
shown by a up field shift of the OH peak (to the lower wave number). A greater degree of 289 
structural constraint appeared also to be present in the OH groups of the polymer when the fully 290 
hydrolysed PVA was the major component of the lorazepam microparticle coat, the OH peak 291 
occurred at 3200 cm
-1
 for the Lorzpva microparticle (Figure 1), but ca. 3100 cm
-1
 for the 292 
HyLorzpva microparticle (again an up field shift, data not shown). The HwLorzpvp showed even 293 
more extensive hydrogen bonding compared to the PVA dominated coats with a OH peak at 294 
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3062 cm
-1 
(Figure 2), but the HpLorzpvp retained a low field absorbance of 3357 cm
-1
 (data not 295 
shown). The changes in the OH region were mirrored by the C=O spectral shifts, that is, the 296 
adsorption of the polymers resulted in a downfield displacement of the C=O peak, except for the 297 
HpLorzpvp microparticle which was the only system to record at C=O peak at ca. 1730 cm
-1
 (data 298 
not shown). Interestingly, the strong, sharp lorazepam absorbance bands recorded at 3356 and 299 
3458 cm
-1
 for the hydroxyl group at position C3 of the diazepine ring that were present when the 300 
HyLorzpva and HwLorzpvp microparticles were analysed lost their distinction when both the 301 
HpLorzpvp and Lorzpva particles were assessed (Figures 1 and 2).     302 
 303 
Particle Aerosolisation 304 
 305 
The lorazepam recovery from all the aerosolisation assessments was in the range of 95 – 115% 306 
and this illustrated that the aerosolisation test system was fit for purpose. The deposition of the 307 
particles when the uncoated lorazepam was aerosolised into the impactor appeared to be evenly 308 
distributed across the 4 collection stages. This is typical behaviour for a polydisperse 309 
microparticle with a particle diameter of approximately 7 µm that did not significantly aggregate 310 
upon aerosolisation (Figure 3). The lack of significant aggregation of the uncoated lorazepam 311 
was reflected in the mass median aerodynamic diameter (MMAD) of ca. 6 µm, i.e. a value that 312 
was similar to the volume median diameter (ca. 7 µm) for the same material. Although MMAD 313 
takes into account density this was assumed to be relatively constant and close to 1 g/cm
3
 across 314 
the powders as the drug core was suspended in the feed stock in all the systems. Scanning 315 
electron micropscopy (SEM) analysis showed that the particles had a smooth external surface 316 
without pores supported this (data not shown, morphology identical to that reported in (Jones et 317 
al., 2006a). HyLorzpva, HwLorzpvp and HpLorzpvp behaved in a similar manner to the uncoated 318 
lorazepam whereby the particle MMAD was similar to their volume mean diameter (VMD) and 319 
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this indicated that the particles that were aerosolised into the impactor were not aggregated. The 320 
Lorapva microparticle delivered approximately 4 times more lorazepam (significantly higher than 321 
the uncoated lorazepam, p < 0.05) into the first stage of the impactor and this resulted in an 322 
MMAD of 32 µm. This deposition pattern was indicative of significant aggregation post 323 
aerosolisation which is typically observed from a cohesive powder. Between 30-40% of the total 324 
dose was retained by the delivery device. This was consistent across the 4 powders and was a 325 
function of the efficiency of the device to fluidise the powder bed. 326 
 327 
Dissolution Testing 328 
 329 
Measuring the dissolution rate for the microparticles was extremely difficult because the 330 
microfine polymer coat aided particle wetting and thus the rate at which the drug was released so 331 
rapid. It was not physically possible to take enough samples within a very short time course 332 
when the steady state release was established. Therefore, both non-micellar (0.2%, w/v) and 333 
miclellar (0.5%, w/v) SDS solutions were employed as the dissolution media to qualitatively 334 
evaluate and rank the dissolution rate of different particle systems. Using 0.2% and 0.5% SDS, 335 
the only rate that could be measured with any degree of certainty was the HyLorzpva which 336 
released the drug at a zero order release constant of 0.014 in 0.2% SDS (0-60 min) and 0.046 in 337 
0.5% SDS (0-15 min). This trend, that is a more rapid dissolution rate in the dissolution media 338 
that contained 0.5% SDS, was evident throughout the dissolution results to the extent that the 339 
dissolution profiles in both media provided an identical rank order in terms of dissolution speed 340 
(Figure 4 and 5). In the absence of reliable rate measurements, the extent of drug release in 5 341 
min (D5min) provided an appropriate index with which to compare the lorazepam release rate 342 
from the microparticles. The D5min for uncoated lorazepam in the media containing 0.2% SDS 343 
was 53% and for the media in 0.5% SDS it was 75%. Upon addition of a microparticle coat 344 
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containing fully hydrolysed PVA the dissolution rate of the drug was reduced (D5min 14% and 345 
33% for 0.2% and 0.5% SDS, respectively) whilst each of the other polymer coats improved the 346 
rapid drug dissolution. For example the HpLorzpvp coat increased D5min from 53% to 90% in the 347 
medium with 0.2% SDS (Figure 4).   348 
 349 
DISCUSSION 350 
 351 
The particle size of a formulation presented to the nasal cavity plays an important role in the 352 
deposition and clearance of the drug that it releases. Therefore developing a dry powder for 353 
intranasal administration that displays adequate chemical stability, flow, aerosolisation 354 
characteristics and drug release can be a time consuming and costly process. There is, as with 355 
pulmonary delivery, no clear consensus among researchers as to what is the ‘ideal’ particle size 356 
for a nasal delivery. However, previous work has suggested that a powder with a high proportion 357 
of particles with a size of less than 1 μm has the potential to cause undesired toxicity due to 358 
lower respiratory tract deposition (Chien and Chang, 1987; Hinchcliffe and Illum, 1999). 359 
Particles with size of above 10 μm are thought to almost exclusively deposit in the nasal cavity 360 
when inhaled directly into the nose (depending on the method by which they are aerosolised) 361 
although most of the marketed locally acting formulations dose a population of particles that is 362 
closer to 100 µm (Chien and Chang, 1987; Hinchcliffe and Illum, 1999)
 
. Considering that rapid 363 
drug dissolution was desirable in this work, a size of between 5-10 µm, under normal 364 
administration conditions, was considered the preferred size for lorazepam (Lansley and Martin, 365 
2001; Sinko, 2006).  366 
 367 
Producing an intermit mixture of drug and excipients in a small microparticle is technically 368 
challenging using equipment that is capable of large scale production. Particle size was 369 
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considered as the critical parameter to keep consistent across the powders if the fundamental 370 
interactions and drug release from the particles were to be investigated. In the current study by 371 
varying the grade of polymer, quantity of polymer and coating thickness a series of particles 372 
with similar diameters were generated and this allowed the particle surface to be modified whilst 373 
retaining a relatively consistent particle surface area. Large differences in particle surface area or 374 
disaggregation can often dominate both dissolution and cohesion and hide underlying 375 
composition effects. It therefore must be accepted that it was not feasible to control particle 376 
coating thickness (which was related to lorazepam content) or incrementally change excipient 377 
composition across these studies. Any effect that this design had on result interpretation is 378 
clarified at each stage of the subsequent discussion.  379 
 380 
Buttini et al. (2008b) found that vinyl polymer adsorption was a multi-layered process that 381 
allowed high loads of polymers to be captured on a microparticle surface. The consequence of 382 
the high polymer loading capacity is that the initial drug-polymer ratios are roughly maintained 383 
during spray-drying. The lorazepam microparticles generated in this work demonstrated an 384 
identical trend which was considered indicative of a similar multilayer absorption process 385 
occurring. Although the extent of adsorption is known to be a consequence of the substrate and 386 
polymer-surface interactions, the adsorption process was not quantified in this work as it had 387 
been in the previous study (Buttini et al., 2008b). The focus was to investigate the molecular 388 
interactions and functional effects of the polymer coat on the delivery characteristics.  389 
 390 
Thermal analysis was used to determine the lorazepam response to polymer adsorption. The shift 391 
in the melting point of the drug that had been coated by the polymers suggested that there was a 392 
strong interaction between vinyl polymers and the lorazepam. Of the three known lorazepam 393 
polymorphs, the crystalline melt observed in this work indicated the presence of the most stable 394 
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form, which is known to form a dimer in the solid state (Jug and Becirevic-Lacan M, 2008). The 395 
high lorazepam melt enthalpy (245 J/g) was similar to the high value reported previously (ca. 396 
190 J/g) (Jug and Becirevic-Lacan M, 2008) and therefore the dimer formation theory associated 397 
with this high value was applicable in this work. If this was assumed to be the case, the melting 398 
point shift, when the polymer coat was added to the lorazepam, was most probably a result of the 399 
polymers disrupting the drug dimer hydrogen bond formation. The alternative hypothesis, i.e., 400 
that the drug may convert to a less stable polymorph or an amorphous material, would appear 401 
unlikely given the lack of any re-crystallisation transitions in the thermal profiles and the lack of 402 
water absorption by the powders. The possibility of dimer formation made the calculation of the 403 
powder crystallinity complex. In this work the production method, i.e. spray-drying from a drug 404 
suspension, the relatively low solubility of the drug and the surface adsorption of the polymers 405 
meant that it would be very unlikely that any amorphous material generated would be 406 
incorporated into the surface of the particles and thus confound the conclusions from the 407 
subsequent particle assessment. Therefore more in-depth solid state analysis was not conducted. 408 
 409 
The presence of two vinyl polymers and the lorazepam in the four coated microparticle systems 410 
made precise infrared spectral assignments difficult. However, it was clear from the recorded 411 
traces that the type, nature and extent of hydrogen bonding in the materials used in this work 412 
was critical to the nature of polymer coat. The most extensive polymer adsorption was 413 
associated with a loss in the sharp lorazepam absorbance bands for the hydroxyl group at 414 
position C3 of the lorazepam diazepine ring, the most extensive changes in the thermal profiles 415 
and the appearance of a new C=O peak down field which represented the release of the 416 
constraints imposed upon this functionality by the polymer hydrogen bonding. These results 417 
suggest the partially hydrolysed PVA adsorbs to the lorazepam surface by hydrogen bonding 418 
with the C3 of the lorazepam diazepine ring (Figure 6). This adsorption process releases the 419 
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constraints on the acetate group of the partially hydrolysed PVA as it is removed from close 420 
association with the alcohol groups which form strong hydrogen bonds. This acetate group is 421 
known to disrupt the alcohol hydrogen bonding and therefore affect the orientation of this group 422 
towards the particle surface theoretically allowing the PVA alcohols to form new hydrogen 423 
bonds as described previously (Jones et al., 2005). Fully hydrolysed PVA retains a greater 424 
structural rigidity upon adsorption according to the FTIR spectra, which is not unexpected as the 425 
few acetates that are present have little disruption effect on the alcohol groups in PVA. 426 
Employing fully hydrolysed PVA as the main component in the microparticle coat resulted in a 427 
less disruption of the lorazepam dimers which suggests weaker polymer adsorption. In terms of 428 
the effect of PVP on adsorption, low MW is preferred as the high MW would increase the 429 
solution viscosity hindering the migration of polymer to the drug surface. In addition, the 430 
stronger interaction between PVP and highly hydrolysed PVA in solution would also deter the 431 
adsorption process (Jones, et al., 2005). This was supported by the missing lorazepam 432 
characteristic peak at 3356 and 3458 cm
-1
 in Lorzpva and HpLorzpvp and the fact that both showed 433 
higher polymer contents compared to HyLorzpva and HwLorzpvp.  434 
 435 
The most widely employed approach to formulating dry powder aerosol delivery systems for 436 
pulmonary drug delivery is to combine the drug particles with coarse carrier such as lactose which 437 
can aid powder flow, aersolisation and act as a bulking agent. Upon delivery, the adhesion forces 438 
between drug particles and the carrier must be overcome to enable the efficient aerosolisation of 439 
the former. However, the interactions between the drug particles and course carrier, e.g. the 440 
adhesive and cohesive forces between the components of the systems, may heavily disturb the 441 
aerosolisation of drug particles (Murnane et al., 2009; Young et al., 2009). In addition, the 442 
presence of a third component, ‘fine lactose’ particles, which always accompany lactose carrier 443 
in commercially sourced material, make the aerosolisation behaviour of the drug particles more 444 
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complicated and difficult to control (Jones and Price, 2006). In powders intended for nasal 445 
delivery a carrier such as lactose is typically not employed. The coated microparticles produced 446 
in this work were flowable, a carrier was not needed and this simplified the formulation approach 447 
and made it suitable for nasal delivery.  448 
 449 
The MSLI apparatus that is specified both in United States Pharmacopeia and European 450 
Pharmacopeia is widely accepted and utilized to evaluate the aerosolisation of drug power 451 
formulations via the determination of particle size distribution. The particles collected before 452 
stage 3 can be considered to theoretically deposit in the nasal cavity, however simply adding up 453 
the amount deposited in the nose provides little mechanistic information with regard to the 454 
material’s aerosolisation properties or cohesion. A much more useful index that can be drawn 455 
out from the deposition data is the MMAD. The comparison of MMAD with the original VMD 456 
of the material prior to aerosolisation has previously been reported to provide an insight into the 457 
dominant microparticle forces that influence a powder upon aerosolisation (Buttini et al., 2008a). 458 
In this work such a comparison showed that only one microparticle system appeared to be 459 
cohesive after fluidisation by airflow, Lorzpva, which was the microparticle coat which appeared 460 
to interact most strongly with the surface of the lorazepam. This suggests that the breaking of the 461 
PVA hydrogen bonds during the adsorption process has two effects: 1.) it increases the ability to 462 
form new interactions with other excipients or solvents and 2.) it increases the ability to form 463 
particle-particle bonds resulting in increased cohesion. It is acknowledged that particle 464 
aerosolisation is not only influenced by the excipient properties (Minne et al., 2008), but also the 465 
particle size (Donovan and Huang, 1998), density (Ting et al., 1992), morphology (Crowder et 466 
al., 2002) and surface roughness (Tang et al., 2004), however in this work these were all 467 
approximately equivalent.   468 
 469 
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Due to deleterious influence of high MW PVP on adsorption, the dissolution profile of 470 
HwLorzpvp was not examined. Ideally the in vitro dissolution test of the coated lorazepam 471 
particles should be performed using the artificial nasal fluids (ANF) that contain mucins, a 472 
family of high molecular weight, heavily glycosylated proteins (Baumann et al., 2009). However, 473 
as the chemical stability of lorazepam in the ANF was unknown and the presence of 474 
glycosylated proteins would increase the complexity of the HPLC analysis an SDS loaded 475 
aqueous solution was used as the mimetic media in this work. The critical micelle concentration 476 
(CMC) of SDS at 37
o
C has been reported to be ca. 0.25% (w/v) (Goddard and Benson, 1957) 477 
and this resulted in two concentrations of the SDS being used in the work, 0.2 and 0.5% (w/v), 478 
that is, one system which formed SDS micelles and one that did not. Although the presence of 479 
micelles did speed up the dissolution they did so evenly across the microparticles and hence the 480 
media employed to test the drug release did not have a significant effect on result interpretation. 481 
Generating an artificial surfactant based fluid in which to test drug release was not ideal and 482 
probably limited the capacity of the release assay to discriminate between the powders tested. 483 
However, the benefits of testing the drug release under sink conditions where drug solubility, 484 
which was impossible to finely control, did not confound the results was considered more 485 
important than mimicking in vivo conditions. It is important that the differences in release across 486 
the powders, although appear to be relatively small are interpreted with this experimental design 487 
consideration in mind as such differences increase dramatically as the surfactant concentration is 488 
lowered. 489 
 490 
The superior release of the lorazepam from the microparticles which according the FTIR and 491 
DSC studies underwent most structural re-orientation during the adsorption process was not 492 
surprising. Nor was the fact that the highly hydrolysed PVA polymer which retained the greatest 493 
extent of intra-molecular hydrogen bonding released the lorazepam at the slowest rate. This 494 
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behaviour suggests that the vinyl interactions dominate particle properties and like in previous 495 
work the decreased cohesion between particles and increased wetting, as a result of the greater 496 
conformation freedom of the polymers on the surface of the drug, led to the dissolution profiles 497 
that were generated.  498 
 499 
CONCLUSION 500 
This study demonstrated that the delivery characteristics of lorazepam from microparticles coated 501 
with vinyl macromolecules (PVA and PVP) was probably controlled by a complex equilibrium of 502 
hydrogen bonding. Manipulating the grade and blend of the polymers allowed coats to be formed 503 
around the crystalline lorazepam microparticles with differing degrees of intra-molecular 504 
mobility. Using a vinyl polymer which displayed extensive hydrogen bonding produced the least 505 
cohesive microparticle because the alcohol functional groups were in the main restricted by their 506 
innate intra and intermolecular interactions. The adsorption process did not liberate significant 507 
numbers of the alcohol functional groups to improve the capability of the drug to interact with the 508 
dissolution solvent when fully hydrolysed PVA was used to coat the drug a delay to the drug 509 
release was observed. Breaking the vinyl polymer hydrogen bond network through the 510 
introduction of more acetate groups and a more intensive adsorption process increased the 511 
adhesivity of the polymer in the coat and lead to more extensive solvent interactions thus rapid 512 
drug release. 513 
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List of Tables and Figures 597 
Table 1. Lorazepam suspensions used for the microparticle engineering process. In 598 
each suspension 1gram of lorazepam was suspended in 100 ml of water to which the 599 
polymers were added; PVA and PVP represent poly(vinyl alcohol) and poly(vinyl 600 
pyrrolidone), respectively; the data of PVA hydrolysis was from the products MSDS 601 
(material safety data sheets). K17 and K 90 correspond to a molecular weight of ca. 602 
12,000 and 1300,000, respectively. 603 
 604 
 605 
606 
Formulation PVA (g), (hydrolysis, %) PVP (g) (grade) 
HyLorzpva 0.06, (99)  0.01 (K17) 
Lorzpva 0.6, (88) 0.1 (K17) 
HwLorzpvp  0.06, (88)  0.01 (K90) 
HpLorzpvp 0.06, (88)  0.1 (K17) 
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 607 
Table 2. The characterisation of spray-dried lorazepam microparticles coated with 608 
macromolecules. Data are presented as particle size, drug content, melting point (Tm) 609 
and enthalpy (∆Hf ) (mean ± one standard deviation where appropriate, n = 3-6)   610 
 611 
 612 
 613 
 614 
 615 
616 
Formulation Size (µm) Lorazepam (%) Tm (ºC) ∆Hf (J/g) 
Lorazepam 6.73 ± 0.08 100 189.8 245.7 
HyLorzpva 9.45 ± 0.05 89.28 ±15.05 170.2 13.0 
HwLorzpvp 11.96 ± 0.16 51.72 ±12.64 169.3 13.4 
HpLorzpvp 10.74 ± 0.06 47.04 ± 0.91 156.9 4.8 
Lorzpva 9.85 ± 0.42 38.79 ± 14.00 159.0 6.2 
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Figure 1. A Fourier infrared spectroscopy trace of the fully hydrolysed poly(vinyl 617 
alcohol) (PVA) (top) the partially hydrolysed PVA (middle) and lorazepam with a coat 618 
composed of partially hydrolysed PVA blended with poly(vinyl pyrrolidone) (Lorzpva). 619 
 620 
 621 
622 
Intranasal lorazepam delivery 
 29 
Figure 2. A Fourier infrared spectroscopy trace of the lorazepam (top), lorazepam with 623 
a thin coat composed of partially hydrolysed PVA blended with poly(vinyl 624 
pyrrolidone) (middle HyLorzpva) and lorazepam with a thin coat composed of partially 625 
hydrolysed PVA blended with high molecular weight poly(vinyl pyrrolidone) 626 
(HwLorzpvp). 627 
 628 
 629 
630 
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Figure 3. Aerosolisation of lorazepam and lorazepam coated microparticles into the 631 
Multi-stage Liquid Impinger (MSLI) at the airflow rate of 30 (L.min
-1
). Black bar is 632 
stage 1 (cut off diameter 18.39 µm); light grey is stage 2 (cut-off diameter 9.62 µm); 633 
white is stage 3 (cut-off diameter 4.38 µm) and dark grey is stage 4 (cut-off diameter 634 
2.40 µm). The mass median aerodynamic diameter is displayed above each 635 
formulation in µm. Data are presented as mean ± standard deviation (SD) (n =3-6). 636 
 637 
 638 
639 
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Figure 4. Dissolution profiles of lorazepam from various formulations using 0.2% 640 
(w/v) sodium dodecyl sulfate (SDS) aqueous solution as the dissolution media. 641 
Lorazepam alone (■) was used as control, HyLorzpva (▲) and HpLorzpvp () and 642 
Lorzpva (○), particle composition details can be found in Table 2 (data expressed as 643 
mean ± standard deviation, n = 4-6). 644 
 645 
 646 
647 
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Figure 5. Dissolution profiles of lorazepam from various formulations using 0.5% 648 
(w/v) sodium dodecyl sulfate (SDS) aqueous solution as the dissolution media. 649 
Lorazepam alone (■) was used as control, HyLorzpva (▲) and HpLorzpvp () and 650 
Lorzpva (○), particle composition details can be found in Table 2 (data expressed as 651 
mean ± standard deviation, n = 4-6). 652 
 653 
 654 
655 
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Figure 6. The mode of hydrogen bonding between lorazepam and partially 656 
hydrolysed poly(vinyl alcohol) (PVA). 657 
 658 
